



Novel Therapeutic Approaches in Urothelial Carcinoma

Guest Editors:

Dr. Mimma Rizzo

Division of Medical Oncology,
Azienda Ospedaliero
Universitaria Consorziata
Policlinico di Bari, Bari, Italy

Dr. Patrizia Giannatempo

Department of Medical Oncology,
Fondazione I.R.C.C.S. Istituto
Nazionale dei Tumori, Milan, Italy

Deadline for manuscript
submissions:

closed (30 March 2024)

Message from the Guest Editors

Recently, diagnostic and therapeutic advances have led to lower mortality rates for urothelial carcinoma (UC) patients. The standard of care for advanced UC remains platinum-based combination chemotherapy. However, the therapeutic landscape has been expanded with the Food and Drug Administration's approval of erdafitinib for tumors with a mutation or fusion, which activates fibroblast growth factor receptor (FGFR) 2/FGFR3. Enfortumab vedotin and sacituzumab govitecan are indicated after progression to platinum-based chemotherapy and programmed cell death inhibitor 1/ligand 1.

The increasing number of long-term responders to systemic treatments requires early identification and appropriate management of toxicities.

The next step is the analysis of somatic and germline genomics, aimed at the development of therapies directed at tumor-specific, druggable genetic targets. Identification of specific biomarkers is crucial for developing therapeutic strategies for UC patients.

We invite you to submit papers:

- Genomic and molecular characterization;
- Identification of prognostic and predictive biomarkers;
- Therapeutic perspectives;
- Management of emerging therapies.





medicina



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Edgaras Stankevičius

Medical Academy, Lithuanian
University of Health Sciences,
Kaunas, Lithuania

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), and [other databases](#).

Journal Rank: CiteScore - Q2 (*General Medicine*)

Contact Us

Medicina Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/medicina
medicina@mdpi.com